tbuckley/cabot-search huggingface dataset:
Combination of laparoscopy and hysteroscopy in resection of type III or mass type caesarean scar pregnancy
Authors: Shanshan Zhang, Meifen Wang, Zeying Chai
Journal: BMJ (2019)

From December 2016 to February 2018, 5 patients with type Ⅲ or mass type cesarean scar pregnancy (CSP) were treated in Zhejiang Taizhou Hospital. The clinical features, imaging findings and disease outcome were retrospectively analyzed. There were 3 cases of type Ⅲ and 2 cases of mass type, which were diagnosed by transvaginal ultrasound. The CSPs were resected with combination of laparoscopy and hysteroscopy, the average intraoperative blood loss was 80 ml (50-100 ml) and there were not postoperative complications. The average length of hospital stay was 9.4 days (8-12 d). Postoperative serum β-hCG returned to normal in average 22 days (14-30 d), and the menstruation recovered in 22-39 days after operation. The data indicates that resection of type Ⅲ or mass type caesarean scar pregnancy with a combination of laparoscopy and hysteroscopy is an effective treatment.


Key words: 
Pregnancy; Scar uterus; Cesarean section; Gynecologic surgical procedures
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.
Authors: John D. Powderly, Anthony Tolcher, Patricia LoRusso, Martha Elizabeth Blaney, Daniel Dacosta, William R Henner, Michael Anthony McDevitt, Kathy D. Miller, Talia Golan
Journal: Journal of Clinical Oncology (2020)

TPS3147 Background: CD40 is a key costimulatory molecule for both the innate and adaptive immune systems that is essential for T-cell activation and proliferation. OX40 is a costimulatory molecule that is involved in enhancing nascent immune responses and concomitantly acts to suppress regulatory T-cell activity. ABBV-927 and ABBV-368 are potent agonistic antibodies against CD40 and OX40, respectively. This open-label, Phase 1 study will evaluate the doublet combination of ABBV-927 and ABBV-368 and the triplet combination of ABBV-927, ABBV-368, and the programmed cell death protein-1 (PD-1) inhibitor budigalimab in patients with advanced solid tumors. Methods: For this study (NCT03893955), patients must be ≥18 y with an Eastern Cooperative Oncology Group performance status of 0-1. Patients must have an advanced solid tumor that has progressed on standard therapies. Disease-specific cohorts will include patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Patients with NSCLC must have previously received a PD-1/PD-ligand 1 inhibitor and a platinum-based therapy and no more than one prior immunotherapy. Patients with TNBC must not have received immunotherapy. Patients with uncontrolled central nervous system metastases will be excluded. The recommended Phase 2 dose (RP2D) will first be identified with ABBV-927 + ABBV-368 in patients with solid tumors (Arm A) and will be expanded in disease-specific cohorts including TNBC. The RP2D of ABBV-927 + ABBV-368 + budigalimab will be identified in patients with NSCLC (Arm B). The primary endpoints are determination of the RP2D of ABBV-927 + ABBV-368, the RP2D of ABBV-927 + ABBV-368 + budigalimab, and overall response rate; duration of response, progression-free survival, safety, and pharmacokinetics are secondary endpoints. Screening began on 21 May 2019, and enrollment is ongoing. Clinical trial information: NCT03893955 .
认识甲状腺用好胺碘酮
Authors: 何秉贤
Journal: BMJ (2006)

自著名的心律失常抑制试验(Cardiac arrhythmia suppression trial,CAST)[1]之后,抗心律失常用药有了革命性的变化,Ⅰ类药明显少用,Ⅱ类与Ⅳ类抗心律失常的作用有限,而Ⅲ类药,尤其是胺碘酮,因是惟一具有4类药作用的抗心律失常药,作用强且广,口服一般不抑制心功能,故而广为应用.但因每片胺碘酮200 mg,含有机碘75 mg,且结构似甲状腺素,而正常成人每日需碘仅150～200 μg,因而久用可影响甲状腺功能.原来有甲状腺功能异常者,若未识别,应用胺碘酮则可出现严重问题.目前对甲状腺功能的认识有不少进展,应予复习,以便在临床中更好地应用胺碘酮。
Two regimes of transient intensive insulin therapy in newly diagnosed type 2 diabetic patients
Authors: Zhi-qin Guo, Jing Zhang
Journal: BMJ (2008)

Objective To evaluate two regimes of transient intensive insulin therapy in newly diagnosed type 2 diabetic patients with severe hyperglycemia.Methods Sixty-eight newly diagnosed type 2 diabetic patients with fasting plasma glucose(FPG)≥10.0 mmol/L and glycated hemoglobin A1c (HbA1c)≥8.0％were randomized to either cantinuous subcutaneous insulin infusion(CSII)group or multiple daily injection(MDI)group.Glycemic control,daily dose of insulin,body mass index(BMI),the mean area under the insulin curve(AUC),β-cell function(HOMA-β)and insulin resistence(HOMA-IR) were compared before and after treatment.Results There were no significant differences between two groups in days reaching glycemic control and BMI.The maximal insulin dose for glycemic control in CSII group was(0.53±0.06)U·kg-1·d-1 and that in MDI group was(0.71±0.04)U·kg-1·d-1(t=11.100,P＜0.01).After CSII and MDI treatment,HOMA-β and the mean AUC of insulin were significantly increased(P＜0.01),but there was no significant difference between two groups(P＞0.05).No significant changes in HOMA-IR were observed before and after treatment or between two groups.There were no severe hypoglycemic episodes in two groups and mild hypoglycemic episodes were 0.34％(13/3806)in CSII group and 1.09％(44/4045)in MDI group.Conclusions The excellent glycemic control can be reached by short.terra CSII and MDI treatment in newly diagnosed type 2 diabetic patients with severe hyperglycemia.Lower insulin dose and less mild hypoglycemic episodes seem to be the advantage of CSII regime than MDI regime.β-cell function can be dramatically improved in both therapy regimes.

Key words: 
Diabetes mellitus,type 2;  Insulin; Treatment outcome
A prospective study of event-related potentials in patients with first-episode mild-and-moderate depressions treated with Qishen Fukang Capsules
Authors: Jiu Chen, Lai-qi Yang, Xin-tian Li, Yu Lin, Fan Xu, Qing-hai Fu
Journal: BMJ (2013)

A total of 72 patients with first-episode mild-and-moderate depression took Qishen Fukang Capsules. The change of event-related potential P3 was determined before and after treatment for 6, 12 and 24 weeks. And another 70 healthy controls received the same tests simultaneously. Compared with before treatment, HAMD scores after treatment were lower in the patient group [(29.1±5.1) score vs. (10.4±4.1) score]. P3 latencies were shorter and amplitudes became higher after treatment (P<0.01). And the difference of before and after treatment for 6 weeks was larger than the difference of 12 weeks and after treatment for 6 weeks (P<0.01). The curative effect is definite. And the clinical symptoms and brain evoked potential index have improved in patients with first-episode mild-and-moderate depression after medication.


Key words: 
Qishen Fukang capsules; Event-related potentials
Olaparib monotherapy in pretreated patients with <i>BRCA1/2</i> alterations: Results of a DRUP trial cohort.
Authors: Hanneke van der Wijngaart, Louisa Rose Hoes, Jade Maxime van Berge Henegouwen, Daphne Liselotte van Der Velden, Laurien Zeverijn, Paul Roepman, Luan Nguyen, Erik D. van Werkhoven, Wendy W.J. de Leng, Anne M.L. Jansen, Niven Mehra, Debbie Robbrecht, Hans Gelderblom, Emile E. Voest, Henk M.W. Verheul
Journal: Journal of Clinical Oncology (2020)

3633 Background: Extensive molecular profiling in cancer regularly reveals targets for which approved drugs are available in tumor types outside the registered label. Efficacy of off-label use of these drugs is unavailable. Access to these drugs for pts is challenging. In the Drug Rediscovery Protocol (DRUP, Van der Velden et al, Nature 2019), pts are treated based on their tumor molecular profile. Here, we present the results of the successful cohort “Olaparib for tumors with BRCA1/2 alterations”. Methods: Twenty five adult cancer patients (pts) who exhausted all treatment options and had BRCA1/2 loss of function (LoF) mutations (found in routine diagnostics) were included. No pts were eligible for on-label treatment with PARP inhibitors. Pts were treated with olaparib until disease progression or unacceptable toxicity. The primary endpoint was clinical benefit (CB: objective response or stable disease (SD) ≥ 16 weeks). Pts were enrolled using a Simon-like two-stage model, with 8 pts in stage 1 and up to 24 pts in stage 2 if at least 1 pt had CB in stage 1. A fresh frozen biopsy was obtained from each pt for whole genome sequencing (WGS) and target confirmation. Results: Fourteen pts (56%) had CB. The objective response rate was 32%. Nine different cancer types were included: prostate (n=11), breast (n=4), ovarian (n=2), pancreatic (n=3), colorectal (n=2), biliary tract (n=2), kidney (n=1), adrenal gland (n=1) and endometrial (n=1). WGS could be performed on 58% of baseline tumor biopsies, confirming the original BRCA1/2 mutations in 86%. CB was observed in pts with both somatic and germline BRCA alterations and across tumor types. CB was only observed in cases with biallelic loss of BRCA1/2 in the tumor and when classified as HRD by a pan-cancer homologous recombination deficiency classifier (CHORD), which relies on genome-wide SNV, indel, and SV mutational footprints for HRD detection. No evidence of complete BRCA loss and HRD was observed in 5 pts with PD, while 4 patients with effective BRCA complete loss and HRD also had PD. WGS analysis of these pts suggested resistance mechanisms due to other oncogenic drivers (e.g FGFR1 amplification, CTNNB1 stabilization, KEAP1 inactivation). Conclusions: Olaparib seems to be an effective treatment option for pts with BRCA1/2 LoF mutated malignancies, regardless of histology, for both germline and somatic alterations, which needs confirmation in an independent cohort. CB of olaparib was observed in malignancies showing biallelic loss of BRCA1/2 and when classified as HRD, indicating the importance of the BRCA/HRD signature status. Clinical trial information: NCT02925234 .
Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy (PN) in patients with diffuse large B-cell lymphoma on CALGB 50303 (Alliance).
Authors: Daniel Louis Hertz, Nicholas Bradley Larson, Timothy Pierpont, Nancy L. Bartlett, Andrew David Zelenetz, Wyndham Hopkins Wilson, John Paul Leonard, Sin-Ho Jung, Shaun M. Riska, Kristy L. Richards
Journal: Journal of Clinical Oncology (2020)

e13535 Background: Pediatric patients (pts) receiving long-term vincristine treatment for acute lymphoblastic leukemia (ALL) who carry two variant alleles of CEP72 rs924607 experience more severe peripheral neuropathy (PN) at lower cumulative vincristine doses. The objective of this retrospective pharmacogenetic analysis was to determine if pts homozygous for rs924607 have increased PN risk when receiving short-term vincristine treatment for diffuse large B-cell lymphoma (DLBCL). Methods: Caucasian pts with DLBCL randomized to either of two vincristine-containing regimens (R-CHOP or DA-EPOCH-R) on the CALGB 50303 (Alliance) trial were genotyped for germline rs924607 via TaqMan. Vincristine was administered intravenously 1.4 mg/m 2 (2 mg cap) on day 1 of each R-CHOP cycle (1.4 mg/m 2 /cycle) or 0.4 mg/m 2 /day (no cap) on days 1-4 of each DA-EPOCH-R cycle (1.6 mg/m 2 /cycle). Dosing was repeated every 21 days for 6 treatment cycles, for a maximum cumulative vincristine dose of 8.4 (R-CHOP) or 9.6 (DA-EPOCH-R) mg/m 2 over 18 weeks. The primary analysis compared risk of NCI CTCAE grade 3 or higher PN in rs924607 homozygous variant pts versus wild-type allele carriers using multivariable Cox proportional hazards regression adjusted for treatment received (R-CHOP vs. DA-EPOCH-R), age (continuous), and sex (male vs. female). A secondary analysis was conducted only in pts assigned to the DA-EPOCH-R arm. Results: Of 307 pts included in the analysis, 32 (10.4%) experienced grade 3+ PN. PN occurrence was nominally lower in homozygous pts (5/59 = 8.5%) than wild-type carriers (27/248 = 10.9%). In the primary analysis, homozygous pts did not experience PN earlier in treatment (Hazard ratio (HR) = 1.04, (95% confidence interval: 0.39-2.75), one-sided p-value = 0.47). There was no significant difference between groups in dose-at-PN occurrence (homozygous (n = 5): 8.81 mg/m 2 vs. wild-type carrier (n = 27):6.74 mg/m 2 , p &gt; 0.05). The secondary analysis in pts on the DA-EPOCH-R arm (n = 147), in which the majority of PN events occurred (n = 27/32 = 84%), homozygous pts (n = 26) did not have significantly increased PN risk (HR = 1.30, p = 0.56). Conclusions: This retrospective analysis of the prospective CALGB 50303 trial did not find that pts homozygous for CEP72 rs924607 had increased PN risk during short-term vincristine treatment for DLBCL. Support: U10CA180821, U10CA180882, U24CA196171; https://acknowledgments.alliancefound.org . ClinicalTrials.gov Id: NCT00118209.
Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC).
Authors: Min Yuen Teo, Karissa Whiting, Jose Mauricio Mota, Han Li, Ashley Marie Regazzi, David B. Solit, David Henry Aggen, Chung-Han Lee, Samuel Aaron Funt, Dean F. Bajorin, Irina Ostrovnaya, Gopa Iyer, Jonathan E. Rosenberg
Journal: Journal of Clinical Oncology (2020)

5050 Background: Only a subset of mUC patients (pts) derives benefit from CPI. We sought to evaluate potential clinical and genomic predictors, with additional focus on extreme outcomes. Methods: CPI-treated mUC with tumor sequencing with MSK-IMPACT (up to 468 genes) were identified. Pre-CPI clinical variables (including hemoglobin [hgb], lymphocyte [lymph], neutrophil [neut] and eosinophil [eos] counts) were extracted. Endpoint was time on treatment (ToT). Poor responders were defined as ToT ≤9 weeks and overall survival ≤3 months; exceptional responders had ToT &gt;20 months. A multivariate Cox model for ToT was performed with clinical variables chosen by stepwise selection minimizing Akaike information criterion. Genomic analyses were adjusted for multiple testing. Results: 166/171 identified mUC were evaluable. Median age was 68 years, 78% were male. 72% had bladder primary, while 17%, 35% and 28% had liver, lung and bone metastases (mets). 67% had prior platinum chemo. 24 pts (14%) were poor and exceptional responders, respectively. In univariate analysis, liver mets were associated with shorter ToT while DNA damage repair (DDR) gene alterations, higher body mass index (BMI), eos, hgb and tumor mutation burden (TMB) were associated with longer ToT. No specific genomic alterations achieved q&lt;.05. In multivariate model, prior chemo (HR 1.6, p=.01), liver mets (HR 2.4, p&lt;.01) and high neut were associated with shorter ToT while urethral primary (HR 0.1, p&lt;.01), higher TMB (HR 0.9, p&lt;.01) and higher eos (HR 0.1, p&lt;.01) were independently associated with ToT. Univariate logistic regression to identify poor and exceptional responders are tabulated. Multivariate results will be reported. Conclusions: In addition to validation of various known mUC prognosticators, we observed potential non-linear influence of clinical and genomic factors on extreme outcomes. [Table: see text]
Efficacy and safety of oral anticoagulants in young ischemic stroke patients with non-valvular atrial fibrillation
Authors: Kai Wang, Xiu′e Wei, Liangqun Rong, Lijie Xiao
Journal: BMJ (2017)

Seventy two ischemic stroke patients aged 18-45 years with nonvalvular atrial fibrillation treated in the Second Affiliated Hospital of Xuzhou Medical College from April 2014 to August 2016 were assigned to warfarin group (n=36) and dabigatran group (n=36). In warfarin group the oral warfarin started from small dose and maintained international normalized ratio (INR) as 2.0 to 3.0. In dabigatran group 110 mg dabigatran etexilate was given b. i.d. All patients were followed up for one year after treatment. Medication was discontinued in 10 cases (28%) of warfarin group and 2 cases (6%) of dabigatran group one year after treatment (P=0.02). There were 8 (22%) cases of thromboembolic events in warfarin group and 1 (3%) case in dabigatran group (P=0.03). In warfarin group 233 INR values were recorded with an average of 2.32, and the percentage of time in therapeutic range (TTR) was 75% (174/233). There were 2 deaths in warfarin group and no death in dabiga group. There were 19 (53%) cases of adverse reactions in warfarin group, including 9 cases of bleeding (6 mild bleeding and 3 serious bleeding), 5 cases of nausea and vomiting, 2 cases constipation or diarrhea, 3 cases of headache and dizziness. There were 6 (17%) cases of adverse reactions in dabigatran group, including 2 cases of mild bleeding, 2 cases of nausea and vomiting, 2 cases of constipation or diarrhea. There was significant difference in the incidence of adverse reactions between the two groups(χ2=13.3, P<0.01). The results indicate that the efficacy and safety of dabigatran is superior to that of warfarin for young ischemic stroke patients with nonvalvular atrial fibrillation.


Key words: 
Heart valve diseases; Young; Warfarin; Dabigatran
ögren syndrome complicated with liver damage and itsrelated factors
Authors: 何菁, 李春, 强璐, 苏茵, 栗占国
Journal: BMJ (2010)

：Objective To studyclinical features of liver damage in primary Sj(o)gren syndrome (pSS) and its relatedfactors.Methods One hundred and forty-nine patients of confirmed pSS hospitalized atPeking University People's Hospital were analyzed retrospectively.Results Seventeen of 149patients of pSS (11.4%) showed liver damage,10 diagnosed as autoimmune hepatitis and sevenas primary biliary liver cirrhosis.Increased serum levels of IgG,IgM and γ-globulinaccounted for 88.2% and 50.8%,35.3% and 5.3%,and 94.1% and 47.7% of those complicated withand without liver damage,respectively,with statistically significant difference (P ＜ 0.05).Positive serum anti-mitochondria antibody subtype M2 (AMA-M2)was 35.3% in pSS patients with liver damage,significantly higher than that in thosewithout liver damage (1.5%) (P ＜ 0.05).Independent riskfactors significantly associated with liver damage included age (OR = 1.013,95% CI0.971-1.058),course of illness (OR = 1.089,95% CI 1.032-1.150),serum level of γ-globulin(OR = 4.021,95% CI 1.246-12.982),positive AMA-M2 (OR = 11.82,95% CI 0.005-0.157),andpositive anti-SSA (OR = 101.333,95% CI 12.653-811.560).Conclusions Liver damage occurredrather high in pSS patients and increased serum levels of IgG,IgM,γ-globulinand anti-SSA can be used to predict their complication with liver damage.Age,course ofillness,serum level of γ-globulin,positive AMA-M2 and positive anti-SSA are all significantly associatedwith liver damage in pSS patients.

Key words: 
Sj(o)gren's syndrome;  Hepatitis,autoimmune;  Livercirrhosis,biliary
Characters of germline mutations in Chinese non-small cell lung cancer patients.
Authors: Yuan Qiu, Liping Liu, Qiuhua Deng, Haihong Yang, Hanzhang Chen, Dakai Xiao, Weiwei Li, Wenxi Jiang, Changbin Zhu, Yongping Lin, Jianxing He
Journal: Journal of Clinical Oncology (2020)

e13542 Background: Environment factors are associated with lung cancer occurrence. Genetic susceptibility to lung cancer remains unclear. This study assessed germline mutations in Chinese non-small-cell lung cancer (NSCLC) patients. Methods: 506 FFPE samples were collected from 469 patients pathologically confirmed as lung adenocarcinoma. A 508-gene panel including 63 hereditary cancer genes was applied to detect mutations on MGI-seq 2000. Raw data was processed and analyzed. Variation pathogenicity was categorized following ACMG 2015 guideline. Results: 21 patients (4%) carried (likely) pathogenic (P or LP) mutations in 15 cancer predisposition genes. 11 germline variations included MUTYH (1/21), BLM (1/21), BRIP1(2/21), RAD50(1/21), PMS1(1/21), TP53(1/21), BRCA2(1/2), PALB2(1/21), NF1(1/21), CDH1(1/21) and MRE11A (1/21) genes. Nine likely pathogenic mutations were identified in MRE11A, RAD51C, RAD50, ATR, BRCA2, BLM, PMS1 and VHL genes. These mutations are involved in homologous recombination repair, mismatch repair, Fanconi anemia, and Li-Fraumeni syndrome. Germline mutations were commonly occurred in females (female vs Male: 13 vs 7) without statistical significance. No significant correlations of age of onset and TMB were observed between NSCLC patients with germline wild type and mutation. Other clinical characters like histology and clinical stage presented similar results. Somatic mutations with high frequency like EGFR, KRAS were distributed equally in patients with both germline mutation positive and negative. Conclusions: In this study, there is no significant correlation of germline susceptibility gene mutations with clinical and genetic characters of NSCLC patients. Further investigation on germline genetic aberrations of NSCLC is definitely needed to clarify germline impact on the etiology of NSCLC. [Table: see text]
Growth differentiation factor 15 (GDF-15) inhibition to increase muscle mass and function in cancer cachexia.
Authors: Matthew Peloquin, Brianna LaCarubba, Stephanie Joaqium, Gregory Weber, John Stansfield, Olivier Bezy, Ja Young Kim-Muller, Danna Breen, Zhidan Wu, Bei Betty Zhang
Journal: Journal of Clinical Oncology (2020)

e15633 Background: Almost half of cancer deaths are attributed to cancers most frequently associated with cachexia. Cachexia is a complex metabolic disease characterized by anorexia and unintentional weight loss. Skeletal muscle depletion has been recognized as a key feature of the disease, however muscle anabolic therapies have not been successful, suggesting that treatments that target multiple aspects of the disease will be most effective. Growth differentiation factor 15 (GDF-15) is a cytokine that induces anorexia and weight loss and is associated with cachexia in cancer patients. In preclinical cancer cachexia models, GDF-15 inhibition is sufficient to normalize food intake and body weight, including skeletal muscle mass. However, it remains to be determined whether the increased skeletal muscle mass also results in restoration of muscle function. Therefore, we examined the effect of GDF-15 inhibition on muscle mass and function in mouse models of cancer cachexia in comparison with myostatin inhibition, an established muscle anabolic pathway. Methods: Cachectic mouse tumor models were established with subcutaneous implantation of tumor cell lines reported to be GDF-15-dependent; mouse renal cell carcinoma (RENCA) and human ovarian cancer (TOV-21G) cell lines. Mice were treated with anti-GDF-15 (mAB2) or anti-myostatin (RK35) monoclonal antibodies and skeletal muscle function was assessed in vivo via maximum force, maximum rate of contraction and half relax time. In the RENCA tumor model, GDF-15 inhibition fully restored body weight and skeletal muscle mass whereas myostatin inhibition showed only a modest effect. Results: Consistent with the muscle mass improvement, GDF-15 inhibition dramatically increased functional muscle endpoints compared to the partial effect of myostatin inhibition. Interestingly, in the TOV-21G tumor model GDF-15 inhibition only partially restored body weight, however skeletal muscle mass and muscle function were completely normalized. Consistent with the functional assessment, GDF-15 inhibition in the RENCA tumor model decreased the expression of several catabolic genes (i.e. Trim63, Fbxo32, Myh7 and Myh2). The GDF-15 effect is likely to be secondary to the reversal of anorexia since wildtype mice pair-fed to Fc-GDF-15-treated mice demonstrated equivalent muscle mass loss. Conclusions: Taken together these data suggest that GDF-15 inhibition holds potential as an effective therapeutic approach to alleviate multiple aspects of cachexia.
铜离子治疗内痔出血123例体会
Authors: 凌红卫, 常宝志, 关大顺
Journal: BMJ (2006)

通过铜离子治疗仪,将铜离子输入痔核内微血管区并形成铜络合物,使痔核萎缩变小,被吸收,用此方法治疗内痔及混合痔出血123例.治疗后,120例出血停止,内痔萎缩;2例再次治疗出血停止,内痔萎缩;1例再行2次治疗出血停止.全部病例均未出现肛门功能障碍及其他并发症.铜离子治疗仪治疗内痔出血起效快,复发率低,治疗在直视下完成,操作简单、安全,患者痛苦轻,不影响生活和工作,疗效满意。
2型糖尿病患者外周大血管重构与心脏结构和功能的变化
Authors: 倪长霖, 汤云昭, 贾艳坤, 邢岩
Journal: BMJ (2007)

对194例2型糖尿病(T2DM)患者,超声检测股动脉、颈动脉内膜和心脏结构,并依动脉狭窄情况分为4组.结果 ,动脉狭窄组的左房大于动脉正常组;双动脉狭窄组的左室大于颈动脉狭窄组;双动脉狭窄组的左心室射血分数低于颈动脉狭窄组和正常组.提示外周动脉病变程度和累及支数与心脏结构和功能有明显相关性。